Milk Allergy Clinical Trial
Official title:
Xolair (Omalizumab) Enhances Oral Tolerance Induction in Milk Allergic Children
NCT number | NCT00968110 |
Other study ID # | Milk-01 |
Secondary ID | |
Status | Completed |
Phase | Early Phase 1 |
First received | |
Last updated | |
Start date | March 2009 |
Est. completion date | April 2017 |
Verified date | September 2018 |
Source | Boston Children’s Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a pilot feasibility study, using Xolair pretreatment for oral milk desensitization. The major assessment will be safety, and the investigators will evaluate for any type of reaction, including allergic reactions that occur during the course of the study.
Status | Completed |
Enrollment | 10 |
Est. completion date | April 2017 |
Est. primary completion date | April 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Years to 18 Years |
Eligibility |
Inclusion Criteria: - Moderate to severe pediatric cow's milk allergy-sensitive subjects between the ages of 4-18 years old. - Total IgE >30 kU/L - Sensitivity to cow's milk allergen will be documented by a positive skin prick test result (see Appendix E for details) and RAST test to cow's milk, with 25 kU/L as a lower limit of eligibility. Patients who do not meet the cow's milk RAST requirement may be eligible for this study if they have a history of a moderate to severe reaction, and if they have recently failed an oral food challenge with milk ordered by their physician. - All female subjects of child-bearing potential will be required to provide a urine sample for pregnancy testing that must be negative one week before being allowed to participate in the study. - Subjects must be planning to remain in the study area during the trial. - Subjects and/or their parents must be trained on the proper use of the Epi-Pen to be allowed to enroll in the study. Exclusion Criteria: - No absolute contraindications to allergen skin testing and/or oral ingestion of milk are known. However, the risk of serious systemic anaphylactic reactions to milk suggests a number of preexisting conditions that should be considered relative contraindications. Among those conditions are acute infections, autoimmune disease, severe cardiac disease, and treatment with beta-adrenergic antagonistic drugs (beta-blockers). - Subjects having a history of severe anaphylaxis to milk requiring intubation or admission to an ICU, frequent allergic or non-allergic urticaria, or history consistent with poorly controlled persistent asthma. - Total IgE > 2000 IU/mL. - Subjects with unstable angina, significant arrhythmia, uncontrolled hypertension, chronic sinusitis, or other chronic or immunological diseases that in the mind of the investigator might interfere with the evaluation or administration of the test drug or pose additional risk to the subject e.g. gastrointestinal or gastroesophageal disease, chronic infections, scleroderma, hepatic and gallbladder disease, chronic non-allergic pulmonary disease. - Subject with an FEV1 or PEF less than 80% predicted (moderate persistent asthma) with or without controller medication (if able to perform the maneuver) at screening, the oral desensitization visit, or food challenge visit. - Subjects who have received an experimental drug in the last 30 days prior to admission into this study or who plan to use an experimental drug during the study. - Subjects who are current users of oral, intramuscular, or intravenous corticosteroids, tricyclic antidepressants, or are taking a beta-blocker (oral or topical). - Subjects routinely using medication that could induce adverse gastrointestinal reactions during the study. - Subjects refusing to sign the EpiPen Training Form (see Appendix F). - Pregnant or breast feeding females. - Subjects with a history of rice and soy allergy. |
Country | Name | City | State |
---|---|---|---|
United States | Children's Hosptial Boston | Boston | Massachusetts |
United States | Stanford Uneiversity Medical Center | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Boston Children’s Hospital | Stanford University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The major goal of this study is to assess the safety of Xolair in young children, and the safety of oral desensitization in patients pretreated with Xolair | week 53 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01950533 -
The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy
|
||
Completed |
NCT02579876 -
Milk Patch for Eosinophilic Esophagitis
|
Phase 2 | |
Completed |
NCT04318483 -
Characteristic and Evolution of an Atypical IgE-mediated Cow Milk Allergy Form With Hands and Feet Angio-oedema
|
||
Completed |
NCT02317952 -
Formula for Children With Cow's Milk Allergy
|
N/A | |
Recruiting |
NCT03309488 -
Basophil Activation Test to Diagnose Food Allergy
|
||
Completed |
NCT00328731 -
Milk ALLERGY ELIMINATION THROUGH NAET® (Nambudripad's Allergy Elimination Techniques).
|
Phase 1/Phase 2 | |
Recruiting |
NCT05309772 -
The Clinical Impact of the Basophil Activation Test to Diagnose Food Allergy
|
N/A | |
Terminated |
NCT02719405 -
Impact of Infant Formula on Resolution of Cow's Milk Allergy
|
Phase 2 | |
Completed |
NCT01361347 -
Safety of Oral Immunotherapy for Cow's Milk Allergy in School-aged Children
|
Phase 4 | |
Completed |
NCT01157117 -
OIT and Xolair® (Omalizumab) in Cow's Milk Allergy
|
Phase 2 | |
Active, not recruiting |
NCT00732654 -
The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy
|
Phase 1/Phase 2 | |
Recruiting |
NCT03819556 -
Swedish Study of Immunotherapy for Milk Allergy in Children
|
N/A |